Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

First Parkinson's Patients Treated in Landmark Phase 2 Trial of Dapansutrile - Expanding a Leading Oral NLRP3 Inhibitor into Neurological Diseases

Olatec Therapeutics, Inc. ("Olatec"), developing one of the most clinically advanced specific oral NLRP3 inhibitors, dapansutrile, today announced that two patients have been randomized in a 12-month clinical trial, named DAPA-PD, for the treatment of Parkinson's disease (PD).

March 24, 2026


March 26 2026

March 25 2026

March 24 2026

March 23 2026

March 22 2026

March 21 2026

March 20 2026

March 19 2026

March 18 2026

March 17 2026

March 16 2026

March 15 2026

March 14 2026

March 13 2026

March 12 2026